Hatim Sabaawy
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organoids | 3 | 2021 | 141 | 1.810 |
Why?
| | Polycomb Repressive Complex 1 | 3 | 2026 | 66 | 1.020 |
Why?
| | Neoplastic Stem Cells | 3 | 2016 | 412 | 0.990 |
Why?
| | Prostatic Neoplasms | 3 | 2021 | 974 | 0.940 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 2194 | 0.920 |
Why?
| | Glioblastoma | 2 | 2021 | 353 | 0.850 |
Why?
| | Bone Marrow Cells | 3 | 2014 | 320 | 0.810 |
Why?
| | Spinal Cord Injuries | 4 | 2014 | 240 | 0.750 |
Why?
| | Zebrafish | 9 | 2022 | 528 | 0.740 |
Why?
| | Bone Marrow Transplantation | 2 | 2014 | 294 | 0.730 |
Why?
| | Cell Culture Techniques | 2 | 2021 | 375 | 0.710 |
Why?
| | Janus Kinases | 1 | 2021 | 20 | 0.710 |
Why?
| | STAT Transcription Factors | 1 | 2021 | 24 | 0.710 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2012 | 186 | 0.700 |
Why?
| | Biological Assay | 1 | 2021 | 128 | 0.680 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 928 | 0.650 |
Why?
| | Hepatocytes | 1 | 2021 | 223 | 0.640 |
Why?
| | Hematopoietic Stem Cells | 3 | 2012 | 420 | 0.630 |
Why?
| | Precision Medicine | 2 | 2021 | 457 | 0.590 |
Why?
| | Cell Survival | 4 | 2016 | 1098 | 0.510 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 111 | 0.480 |
Why?
| | Cell Self Renewal | 1 | 2016 | 53 | 0.480 |
Why?
| | Erythroid Cells | 2 | 2012 | 8 | 0.470 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2017 | 370 | 0.470 |
Why?
| | Zebrafish Proteins | 4 | 2022 | 311 | 0.460 |
Why?
| | Cell Differentiation | 3 | 2012 | 2050 | 0.460 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 43 | 0.440 |
Why?
| | Quinoxalines | 1 | 2015 | 65 | 0.430 |
Why?
| | Nanotechnology | 1 | 2015 | 126 | 0.420 |
Why?
| | Adenocarcinoma | 3 | 2013 | 928 | 0.420 |
Why?
| | Nerve Regeneration | 1 | 2014 | 56 | 0.420 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2022 | 436 | 0.410 |
Why?
| | Benzimidazoles | 1 | 2015 | 190 | 0.400 |
Why?
| | Brain Neoplasms | 2 | 2021 | 1318 | 0.400 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 161 | 0.390 |
Why?
| | Liver Neoplasms | 2 | 2017 | 780 | 0.390 |
Why?
| | Liver | 1 | 2021 | 1887 | 0.380 |
Why?
| | Megakaryocytes | 1 | 2012 | 34 | 0.370 |
Why?
| | Embryonic Development | 2 | 2013 | 125 | 0.370 |
Why?
| | Cell Adhesion | 1 | 2013 | 455 | 0.360 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2012 | 30 | 0.340 |
Why?
| | Cell Line, Tumor | 6 | 2022 | 3540 | 0.340 |
Why?
| | Inflammation | 1 | 2021 | 2878 | 0.320 |
Why?
| | Hep G2 Cells | 2 | 2021 | 74 | 0.310 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1716 | 0.310 |
Why?
| | Signal Transduction | 2 | 2021 | 5226 | 0.310 |
Why?
| | Animals | 21 | 2026 | 38058 | 0.290 |
Why?
| | Brain | 2 | 2021 | 2933 | 0.290 |
Why?
| | Exercise Therapy | 1 | 2013 | 473 | 0.270 |
Why?
| | Fluorouracil | 2 | 1999 | 235 | 0.270 |
Why?
| | Interferon-alpha | 2 | 1999 | 197 | 0.270 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 336 | 0.260 |
Why?
| | Receptors, Androgen | 2 | 2020 | 153 | 0.260 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2007 | 14 | 0.260 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2021 | 339 | 0.250 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 610 | 0.250 |
Why?
| | Lymphoproliferative Disorders | 1 | 2007 | 57 | 0.250 |
Why?
| | Colonic Neoplasms | 2 | 1999 | 259 | 0.250 |
Why?
| | Cell Proliferation | 4 | 2021 | 2496 | 0.240 |
Why?
| | Apoptosis | 6 | 2020 | 2430 | 0.240 |
Why?
| | Neoplasms | 1 | 2021 | 2875 | 0.240 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 881 | 0.240 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 124 | 0.230 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2026 | 38 | 0.230 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 432 | 0.230 |
Why?
| | Heterochromatin | 1 | 2026 | 67 | 0.230 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 89 | 0.230 |
Why?
| | Disease Models, Animal | 4 | 2014 | 4557 | 0.220 |
Why?
| | F-Box Proteins | 2 | 2016 | 23 | 0.220 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2026 | 81 | 0.220 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2001 | 21 | 0.220 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2006 | 210 | 0.210 |
Why?
| | Humans | 27 | 2023 | 144759 | 0.210 |
Why?
| | Mice | 9 | 2026 | 18339 | 0.210 |
Why?
| | Transplantation, Autologous | 3 | 2014 | 290 | 0.210 |
Why?
| | Morpholinos | 2 | 2013 | 29 | 0.190 |
Why?
| | Ear, Inner | 1 | 2022 | 51 | 0.180 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2021 | 15 | 0.180 |
Why?
| | Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2021 | 13 | 0.180 |
Why?
| | Glucose-6-Phosphatase | 1 | 2021 | 31 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 1999 | 105 | 0.180 |
Why?
| | Genetic Therapy | 2 | 2001 | 313 | 0.180 |
Why?
| | Cell Shape | 1 | 2021 | 57 | 0.180 |
Why?
| | Freezing | 1 | 2021 | 86 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1266 | 0.170 |
Why?
| | Culture Media | 1 | 2021 | 161 | 0.170 |
Why?
| | SOX9 Transcription Factor | 2 | 2023 | 28 | 0.170 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 62 | 0.170 |
Why?
| | Albumins | 1 | 2021 | 118 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 191 | 0.170 |
Why?
| | Gene Transfer Techniques | 2 | 1999 | 185 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 194 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 370 | 0.160 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 61 | 0.160 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 732 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 143 | 0.160 |
Why?
| | Tumor Cells, Cultured | 3 | 2015 | 919 | 0.160 |
Why?
| | Histological Techniques | 1 | 2020 | 38 | 0.160 |
Why?
| | Prodrugs | 1 | 2021 | 52 | 0.160 |
Why?
| | Biomarkers | 2 | 2021 | 4271 | 0.160 |
Why?
| | Androgen Antagonists | 1 | 2020 | 91 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.160 |
Why?
| | Gene Expression | 3 | 2012 | 1490 | 0.150 |
Why?
| | Printing, Three-Dimensional | 1 | 2020 | 96 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2637 | 0.150 |
Why?
| | Protein Isoforms | 1 | 2020 | 402 | 0.150 |
Why?
| | Mitosis | 2 | 2012 | 200 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 2021 | 509 | 0.140 |
Why?
| | Recovery of Function | 2 | 2014 | 707 | 0.140 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2608 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 645 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2022 | 641 | 0.130 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2013 | 905 | 0.130 |
Why?
| | Transduction, Genetic | 2 | 2012 | 133 | 0.130 |
Why?
| | Genetic Vectors | 2 | 2012 | 337 | 0.120 |
Why?
| | Male | 10 | 2021 | 72315 | 0.120 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1313 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 834 | 0.120 |
Why?
| | Disease Progression | 2 | 2021 | 2847 | 0.120 |
Why?
| | Retroviridae | 3 | 2001 | 101 | 0.110 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2016 | 159 | 0.110 |
Why?
| | Mice, SCID | 1 | 2016 | 369 | 0.110 |
Why?
| | Neurons | 3 | 2022 | 1640 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 192 | 0.110 |
Why?
| | HEK293 Cells | 1 | 2017 | 744 | 0.110 |
Why?
| | Nanoparticles | 1 | 2021 | 519 | 0.110 |
Why?
| | Blood Pressure | 1 | 2001 | 1769 | 0.110 |
Why?
| | Contusions | 1 | 2014 | 25 | 0.110 |
Why?
| | Spinal Cord | 2 | 2014 | 380 | 0.100 |
Why?
| | Injections, Spinal | 1 | 2014 | 120 | 0.100 |
Why?
| | Racemases and Epimerases | 1 | 2013 | 11 | 0.100 |
Why?
| | Transcriptional Regulator ERG | 1 | 2013 | 14 | 0.100 |
Why?
| | CHARGE Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
| | DNA Damage | 1 | 2016 | 430 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1180 | 0.100 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2013 | 39 | 0.100 |
Why?
| | Dogs | 1 | 2014 | 437 | 0.100 |
Why?
| | Prostate-Specific Antigen | 1 | 2013 | 161 | 0.090 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2013 | 64 | 0.090 |
Why?
| | Collagen Type I | 1 | 2013 | 147 | 0.090 |
Why?
| | Microscopy, Fluorescence | 1 | 2014 | 416 | 0.090 |
Why?
| | Hypertension | 1 | 2001 | 1263 | 0.090 |
Why?
| | Lentivirus | 1 | 2012 | 60 | 0.090 |
Why?
| | K562 Cells | 1 | 2012 | 93 | 0.090 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2013 | 80 | 0.090 |
Why?
| | Antigens, CD34 | 1 | 2012 | 88 | 0.090 |
Why?
| | Cytarabine | 1 | 2012 | 66 | 0.090 |
Why?
| | Erythropoiesis | 1 | 2012 | 57 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 628 | 0.090 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2012 | 56 | 0.090 |
Why?
| | Motor Activity | 2 | 2014 | 721 | 0.090 |
Why?
| | Single-Blind Method | 1 | 2013 | 312 | 0.090 |
Why?
| | DNA Helicases | 1 | 2013 | 143 | 0.090 |
Why?
| | Mice, Nude | 1 | 2013 | 682 | 0.090 |
Why?
| | Embryo, Nonmammalian | 1 | 2012 | 173 | 0.090 |
Why?
| | Organ Specificity | 1 | 2012 | 312 | 0.090 |
Why?
| | Tachykinins | 1 | 2011 | 8 | 0.090 |
Why?
| | Adult | 4 | 2021 | 40449 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3154 | 0.090 |
Why?
| | Spinal Cord Regeneration | 1 | 2011 | 2 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2012 | 194 | 0.080 |
Why?
| | Antigens, CD | 1 | 2014 | 555 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2012 | 160 | 0.080 |
Why?
| | Trans-Activators | 1 | 2013 | 405 | 0.080 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 194 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2027 | 0.080 |
Why?
| | Transcription Factors | 2 | 2022 | 1741 | 0.080 |
Why?
| | Leukemia | 1 | 2012 | 245 | 0.080 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2930 | 0.080 |
Why?
| | Animals, Genetically Modified | 2 | 2007 | 250 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2012 | 499 | 0.070 |
Why?
| | Transfection | 2 | 2020 | 940 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 529 | 0.070 |
Why?
| | Base Sequence | 2 | 2013 | 2190 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2452 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2011 | 437 | 0.070 |
Why?
| | RNA-Binding Protein EWS | 1 | 2007 | 30 | 0.070 |
Why?
| | Nerve Tissue Proteins | 1 | 2011 | 592 | 0.070 |
Why?
| | Immunotherapy | 1 | 2012 | 653 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 157 | 0.060 |
Why?
| | Chronic Disease | 1 | 2013 | 1813 | 0.060 |
Why?
| | bcl-2-Associated X Protein | 1 | 2006 | 54 | 0.060 |
Why?
| | Middle Aged | 4 | 2015 | 35875 | 0.060 |
Why?
| | Polycomb-Group Proteins | 1 | 2026 | 36 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 2832 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1499 | 0.060 |
Why?
| | Single Molecule Imaging | 1 | 2026 | 46 | 0.060 |
Why?
| | Gene Silencing | 1 | 2006 | 205 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1782 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 240 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 701 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2005 | 163 | 0.050 |
Why?
| | Heme Oxygenase-1 | 2 | 2001 | 74 | 0.050 |
Why?
| | Rats | 3 | 2021 | 5597 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1075 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 851 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2007 | 462 | 0.050 |
Why?
| | Female | 6 | 2021 | 78271 | 0.050 |
Why?
| | Genes, ras | 1 | 2023 | 96 | 0.050 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 173 | 0.050 |
Why?
| | Carboplatin | 1 | 2022 | 160 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 253 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 108 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 1054 | 0.040 |
Why?
| | Protein Binding | 3 | 2016 | 2273 | 0.040 |
Why?
| | Pyrazines | 1 | 2022 | 92 | 0.040 |
Why?
| | Culture Techniques | 1 | 2001 | 67 | 0.040 |
Why?
| | Rats, Inbred SHR | 1 | 2001 | 37 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 139 | 0.040 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 293 | 0.040 |
Why?
| | Chimera | 1 | 2001 | 61 | 0.040 |
Why?
| | Paclitaxel | 1 | 2022 | 255 | 0.040 |
Why?
| | Arterioles | 1 | 2001 | 56 | 0.040 |
Why?
| | Neurogenesis | 1 | 2022 | 156 | 0.040 |
Why?
| | Triazoles | 1 | 2022 | 184 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2013 | 11679 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 225 | 0.040 |
Why?
| | Models, Biological | 3 | 2016 | 1821 | 0.040 |
Why?
| | Histones | 1 | 2026 | 669 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 380 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3863 | 0.040 |
Why?
| | Vasoconstriction | 1 | 2001 | 217 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2020 | 73 | 0.040 |
Why?
| | Blotting, Northern | 1 | 1999 | 204 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 156 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 449 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2020 | 166 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1999 | 276 | 0.030 |
Why?
| | Drug Synergism | 1 | 1999 | 357 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 766 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 556 | 0.030 |
Why?
| | Aged | 2 | 2015 | 25913 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 983 | 0.030 |
Why?
| | F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 6 | 0.030 |
Why?
| | Oligonucleotides, Antisense | 2 | 2011 | 116 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 72 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 118 | 0.030 |
Why?
| | Young Adult | 1 | 2013 | 14105 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 173 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 148 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1463 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2001 | 1166 | 0.030 |
Why?
| | Cell Death | 1 | 2016 | 383 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 388 | 0.020 |
Why?
| | Gene Targeting | 1 | 2013 | 82 | 0.020 |
Why?
| | Adolescent | 1 | 2013 | 22428 | 0.020 |
Why?
| | Kidney | 1 | 2001 | 1495 | 0.020 |
Why?
| | RNA, Ribosomal | 1 | 2013 | 168 | 0.020 |
Why?
| | Hepatic Encephalopathy | 1 | 2012 | 25 | 0.020 |
Why?
| | Neural Crest | 1 | 2013 | 126 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2012 | 164 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2012 | 106 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1732 | 0.020 |
Why?
| | Cartilage | 1 | 2013 | 198 | 0.020 |
Why?
| | Activating Transcription Factors | 1 | 2011 | 3 | 0.020 |
Why?
| | Co-Repressor Proteins | 1 | 2011 | 18 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2011 | 55 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2011 | 79 | 0.020 |
Why?
| | Response Elements | 1 | 2011 | 89 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 93 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2011 | 193 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2011 | 76 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 145 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2011 | 275 | 0.020 |
Why?
| | Tretinoin | 1 | 2011 | 124 | 0.020 |
Why?
| | Cell Cycle | 1 | 2013 | 596 | 0.020 |
Why?
| | Child | 2 | 2006 | 22633 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4109 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 784 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1173 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1329 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 396 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 917 | 0.010 |
Why?
| | Preservation, Biological | 1 | 2005 | 7 | 0.010 |
Why?
| | Phenotype | 1 | 2013 | 3162 | 0.010 |
Why?
| | Palliative Care | 1 | 2012 | 1002 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4154 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2155 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5408 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2730 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 7173 | 0.010 |
Why?
| | Tin Compounds | 1 | 2001 | 17 | 0.010 |
Why?
| | Heme | 1 | 2001 | 89 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2001 | 327 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1047 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 4282 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2527 | 0.010 |
Why?
|
|
Sabaawy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|